. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the fourth part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, describes the prominence of underreporting falsified medicines. 

The Hidden Challenge of Reporting Counterfeit Medicines

Articles

Pharma Pulse 7/18/25: How Parexel Supports Cross Functional Trials for Emerging GLP-1 Therapies; Eisai Explores Novel Dual Mechanism Therapy for Advanced Endometrial Carcinoma

In the fourth part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, outlines what he anticipates for the biosimilar adoption curve in key markets moving forward.

The Biosimilar Void

Pharma prepares for looming tariffs, as the US president signals a phased increase starting Aug. 1, but the official starting tax rate is yet to be determined. 

Trump Says Pharma Industry Should Expect Tariffs by Aug. 1

In the third part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, recommends regulatory or verification mechanisms that can help safely legitimize online medicine procurement.

Cracking Down on Illegal Online Pharmacies

Pharma Pulse 7/17/25: Inside the GLP-1 Strategy Driving Competitive Edge in Obesity Clinical Research; Eisai Highlights Long-Term Efficacy of Lenvima in Advanced HCC Treatment

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.

Thermo Fisher, Sanofi Expand Partnership to Boost Sterile Drug Production

In the second part of his Pharma Commerce video interview, Sean O’Hearen, founder and principal consultant at 1st Line Partners, explains how the private sector should strategically support and scale efforts to ensure that HCPs globally receive substandard and falsified medicine detection training. 

Creating a Unified Strategy to Advance Education on Counterfeit Medicines

Executive Vice President at Founder Shield.


Why startups and life sciences companies should approach this booming sector with extreme caution.

The GLP-1 Gold Rush: Why Compounded Alternatives Are a Risky Bet

In the third part of his Pharma Commerce video interview, Murray Aitken, executive director, IQVIA Institute for Human Data Science, explains the strategies that manufacturers should adopt to balance investment in innovation with lifecycle management.

News